U.S. Airlines Stock News

Long term Treasury yields near multi decade highs are reshaping where credit risk feels most exposed. AI and tech stocks tied to heavy spending are being repriced as debt, not just growth stories, which is pulling attention toward listed private credit and alternative lenders. This article walks through three stocks from that universe that appear well positioned relative to these shocks and explains how their exposure to the news could matter for your portfolio. The three listed private...

DXP Enterprises reported past second-quarter 2026 results showing sales of US$576.46 million and net income of US$28.71 million, with both basic and diluted earnings per share from continuing operations higher than a year earlier. Over the first half of 2026, DXP’s higher sales and earnings, alongside prior commentary about strong long-term revenue and earnings-per-share expansion, highlight how its growth initiatives are translating into improved profitability. With this earnings strength...

Trane Technologies (TT) drew investor attention after announcing a collaboration with Eaton focused on integrated thermal management and electrical architectures for AI data centers. The move highlights the stock’s exposure to AI infrastructure and energy efficiency themes. See our latest analysis for Trane Technologies. Trane Technologies’ share price has pulled back in the short term, with a 7 day share price return of 4.25% and a 30 day share price return of 1.41%. Longer term total...

In August 2026, Oruka Therapeutics, Inc. reported second-quarter and six-month results showing net losses of US$41.21 million and US$73.03 million, respectively, with basic loss per share from continuing operations rising to US$0.55 for the quarter and US$1.04 for the half year compared with the prior period. The results highlight that Oruka’s losses and loss per share have increased compared with a year earlier, sharpening investor focus on how the company is funding and pacing its...

AtaiBeckley (ATAI) drew fresh attention after releasing second quarter 2026 results, reporting revenue of US$1.7 million and a net loss of US$32.52 million, while loss per share from continuing operations improved year over year. See our latest analysis for AtaiBeckley. AtaiBeckley’s recent earnings release comes after a sharp shift in sentiment, with a 90 day share price return of 78.24% and a 3 year total shareholder return above 300%, although the 5 year total shareholder return remains...

Semtech recently completed the sale of its cellular module business for US$62,000,000, sharpening its focus on AI data-center networking and LoRa-based connectivity solutions. This portfolio shift marks a clearer emphasis on higher-growth connectivity platforms, potentially reshaping how the company allocates capital and prioritizes innovation across its core segments. We’ll now examine how this exit from the cellular module business may influence Semtech’s broader investment narrative...

In August 2026, Enovis Corporation reported second-quarter 2026 results showing sales of US$582.78 million and a reduced net loss of US$1.19 million, while six-month sales reached US$1.17 billion with a smaller net loss of US$9.95 million compared with the prior year. At the same time, Enovis reaffirmed its 2026 revenue guidance of US$2.31 billion to US$2.37 billion, including 4–6% organic revenue growth, underscoring management’s confidence in the business trajectory despite losses. We will...

Recent Share Performance Context Luckin Coffee (OTCPK:LKNC.Y) has drawn fresh attention after its recent price move, with the stock closing at $36.45 as of 17 August 2026 and showing mixed return patterns across different time frames. Over the past day, week and month, Luckin Coffee has recorded returns of 1.53%, 6.83% and 19.12% respectively. Over the past 3 months, the stock shows an 11.81% gain, while the past year reflects a 3.32% decline. See our latest analysis for Luckin Coffee. The...

Entergy stock has delivered very strong returns over the past three years, yet the current valuation signals are cautious, with the Dividend Discount Model (DDM) implying the shares trade at a premium to its estimated intrinsic value while the broader checks do not point to a clear bargain. Entergy has returned 151.5% over the past three years, which puts recent gains under the spotlight when judging whether the current price still offers an attractive entry point. Expectations for steady...

Erasca (ERAS) is back in focus after reporting second quarter 2026 results that showed a wider net loss, alongside the appointment of veteran oncology leader Charles S. Fuchs as president of research and development. See our latest analysis for Erasca. Erasca’s recent earnings release, shelf registration filing of up to US$112.344 million and the ongoing securities class action have all landed while the stock trades at US$18.10, with a 90 day share price return of 55.97% and a year to date...

Schrödinger (SDGR) is back in focus after reporting second quarter 2026 results that moved from a loss to a profit, along with a new agreement to deploy its Bunsen AI co-scientist with Bristol Myers Squibb. See our latest analysis for Schrödinger. At a share price of $17.67, Schrödinger has seen a 43.4% 90 day share price return and a 15.3% 30 day share price return, although the 1 year total shareholder return is down 8.9%. This suggests recent momentum has picked up following the move to...

Oncolytics Biotech has received FDA feedback supporting a potential pivotal expansion of its REO 033 colorectal cancer trial.

Optimi Health has added financial flexibility to its growth strategy as it advances its MDMA and psilocybin business.

ADMA Biologics (ADMA) stock is back in focus after the company reported second quarter 2026 results, highlighted by US$124.4 million in sales and US$37.82 million in net income, along with reaffirmed full year revenue guidance. See our latest analysis for ADMA Biologics. At a share price of US$9.54, ADMA Biologics has seen a 1 month share price return of 9.53% and a 3 month share price return of 11.45%. However, the year to date share price return is down 46.64%, while the 5 year total...

Graham stock moves after contract wins, earnings update and guidance reaffirmation Graham (GHM) stock has been reacting to a cluster of recent company updates, including more than US$43 million in new defense contracts, first quarter fiscal 2027 results, and reaffirmed full year sales guidance. See our latest analysis for Graham. Graham’s recent contract awards, earnings update and reaffirmed guidance come after a period of strong share price momentum, with a 90 day share price return of...

JBT Marel (JBTM) has drawn investor attention after its latest quarterly report, which paired updated 2026 revenue and earnings guidance with a new share repurchase program and a $0.10 quarterly cash dividend declaration. See our latest analysis for JBT Marel. Even with the stronger second quarter update and fresh capital return plans, JBT Marel’s recent momentum has been weak, with the share price down 14.01% over the last 30 days and 23.48% year to date. The 3 year total shareholder return...

In August 2026, Ligand Pharmaceuticals reported past second-quarter 2026 results showing revenue of US$63.69 million and net income of US$48.51 million, with basic earnings per share from continuing operations of US$2.42, alongside stronger first-half results than the prior year. Importantly for longer-term watchers, Ligand also reaffirmed its 2026 guidance for total revenue of US$270 million to US$310 million and GAAP net income of US$107 million to US$118 million, underscoring...

Texas Capital Bancshares (TCBI) is in focus after Texas Capital Bank Private Wealth Advisors and Texas Capital Funds Trust moved to shift two Texas focused ETFs from the New York Stock Exchange to the new Texas Stock Exchange. See our latest analysis for Texas Capital Bancshares. At a share price of $99.83, Texas Capital Bancshares has seen some recent pressure, with the 1 month share price return down 4.99%. However, the year to date share price return of 8.87% and 1 year total shareholder...

Aveanna Healthcare Holdings Inc. recently reported past second-quarter 2026 results showing sales of US$670.48 million and net income of US$40.29 million, alongside modest impairment charges of US$145,000. Management also raised full-year revenue guidance to more than US$2.68 billion, signaling increased confidence in the company’s operating performance and demand backdrop. We’ll now examine how Aveanna’s raised full-year revenue guidance reshapes its existing investment narrative for...

Charles River Laboratories International (CRL) cut its 2026 earnings guidance after reporting a second quarter net loss and slightly lower revenue. The company also continued its share repurchase program during the same period. See our latest analysis for Charles River Laboratories International. Despite the cut to 2026 earnings guidance and the recent quarterly net loss, Charles River Laboratories International’s share price has risen strongly over recent months, with a 30-day share price...

AI is putting a fresh spotlight on who really profits from personal data, with proposals for $15,000 annual payments to families and talk of a $300b data market and trillion dollar AI IPOs. That debate could reshape how digital payments and benefits infrastructure businesses earn, tax and regulate revenue streams. This article looks at three US stocks exposed to that story and why their future cash flows may matter to your portfolio. The stocks highlighted below are just a sample, and the...

Privia Health Group, Inc. recently reported second-quarter 2026 results showing higher sales of US$632.63 million and improved profitability, and raised its full-year 2026 GAAP revenue outlook to the high end of its prior US$2.35 billion to US$2.45 billion range. The company also appointed experienced healthcare executive and physician Opella Ernest, M.D. to its Board and Compliance Committee, adding deep payer, clinical, and regulatory expertise that could be important as Privia scales its...

Digi International (DGII) drew fresh investor attention after reporting third quarter fiscal 2026 results on 5 August, alongside updated guidance for the fourth quarter and full year revenue. See our latest analysis for Digi International. The earnings release and higher full year revenue guidance arrived after a strong run in Digi International’s stock, with a 30-day share price return of 26.78% and an 87.77% share price return year to date. Over the longer haul, total shareholder return of...

National HealthCare Corporation recently reported past second-quarter 2026 results showing revenue of US$408.03 million and net income of US$40.32 million, alongside strong year-to-date earnings growth versus the prior year period. The company also confirmed it will pay a quarterly cash dividend of US$0.67 per common share to shareholders of record on September 30, 2026, reinforcing its focus on returning cash to investors. We’ll now look at how National HealthCare’s strong earnings growth...